Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00187083 · ClinicalTrials.gov registry record · Phase 3
A Study of Children With Refractory or Relapsed ALL
A Phase 3 study, sponsored by St. Jude Children's Research Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
NCT00187083 is a Phase 3 study that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 40 participants.
The verdict
NCT00187083, a Phase 3 study, has completed, sponsored by St. Jude Children's Research Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
Study Summary
The main purpose of this study is to find out which form of asparaginase (the native E. coli/Erwinia) or PEG-asparaginase) is more effective during induction treatment for children with acute lymphoblastic leukemia that has come back after treatment (relapsed) or is resistant to treatment (refractory)
Interventions
- DRUG Topotecan, dexamethasone, vincristine
- DRUG E. coli Asparaginase, PEG-L-asparaginase
- DRUG erwinia asparaginase
- DRUG fludarabine, methotrexate, mercaptopurine
- DRUG idarubicin, etoposide, cytarbine, teniposide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 1997-02 |
| Est. Completion | 2003-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00187083
The ClinicalTrials.gov registry entry for NCT00187083 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Topotecan, dexamethasone, vincristine is the first listed.
NCT00187083 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00187083 about?
NCT00187083 is a clinical study titled "A Study of Children With Refractory or Relapsed ALL". The main purpose of this study is to find out which form of asparaginase (the native E. coli/Erwinia) or PEG-asparaginase) is more effective during induction treatment for children with acute lymphoblastic leukemia that has come back after treatment (relapsed) or is resistant to treatment (refractor...
What is the current status of trial NCT00187083?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 1997-02. Estimated completion is 2003-12.
What interventions are being tested in trial NCT00187083?
The interventions under investigation include: Topotecan, dexamethasone, vincristine (DRUG), E. coli Asparaginase, PEG-L-asparaginase (DRUG), erwinia asparaginase (DRUG), fludarabine, methotrexate, mercaptopurine (DRUG), idarubicin, etoposide, cytarbine, teniposide (DRUG).
Who is sponsoring clinical trial NCT00187083?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.